Profile Information

Affiliation
professor (professor), department of urology, Fujita Health University
Degree
Medical Doctor(Mar, 1988,  University Hospotal )

Researcher number
90101352
J-GLOBAL ID
202101011761453918
researchmap Member ID
R000023742

 研究分野

神経薬理学、精神疾患の脳科学

①思春期周期性精神病の病態と排卵誘発療法の開発、②覚せい剤精神病の自然再燃:③Schiophreniaにおけるストレス感受性と臼歯ストレス線との関連、④自閉症スペクトラム症の病態と新規治療、⑤結節性硬化症の自閉症を臨床モデルとした治療抵抗性自閉症にペプチド創薬

 

研究業績

英文論文

1.原著

欧文原著

  

1.  Yui, K., Miura, T., Sugiyama, K., Ono, M., Nagase, M.: Methamphetamine plus scopolamine potentiates behavioral sensitization and conditioning. Eur. J. Pharmacol, 1995, 279: 135-142.

2.  Yui, K., Miura, T., Sugiyama, K., Ono, M., Nagase, M.: Comparison of behavioural effects of repeated treatment with methamphetamine plus scopolamine and methamphetamine alone onbehavioural sensitization and conditioned response. J. Pharm. Pharmac, 1995, 47: 852-856.

3.  Yui, K., and Miura, T.: Behavioral responses induced by repeated treatment with methamphetamine alone and in combination with scopolamine in rats. Neuropsychobiology, 1996, 33: 21-27.

4. Yui, K., Goto, K., Ikemoto, S., Ishiguro, T.: Plasma monoamine metabolites and spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory psychosis: Relation of noradrenergic activity to the occurrence of flashbacks. Psychiatry Res,1996, 63: 93-107.

5.  Yui, K., Miura , T., Sugiyama, K., Ono, M., Nagase, M.: Effects of repeated treatment with methamphetamine plus scopolamine and methamphetamine on behavioral sensitization and conditioning. Behav. Brain Res., 1996, 80: 169-175.

6. Yui, K., Goto, K., Ikemoto, S., Ishiguro, T.: Monoamine neurotransmitter function and spontaneous recurrence of methamphetamine psychosis. Ann. N. Y. Acad. Sci, 1996, 801: 415- 429.

7. Yui, K., Ishiguro, T., Okamoto, H.: Infection with GB virus in female prisoners who were drug abusers in Japan. Infection, 1996, 24: 392.

8. Yui, K., Goto K, Ikemoto, S., Ishiguro T.: Methamphetamine psychosis: Spontaneous recurrence of paranoid-hallucinatory states and monoamine neurotransmitter function. J. Clin. Psychopharmacol, 1997, 17: 34-43.

9. Yui, K., Goto, K., Ikemoto, S., Ishiguro, T.: Monoamine neurotransmitter metabolites and spontaneous reccurrence of methamphetamine psychosis. Brain Res. Bull, 1997, 43: 25-33.

10. Yui, K., Goto, K., Ikemoto, S., Ishiguro, T.: Noradrenergic activity and spontaneous recurrence of methamphetamine psychosis. Drug Alcohol Depend, 1997, 44: 183-187.

11. Yui, K., Ishiguro, T., Goto, K., Ikemoto, S.: Precipitating factors in spontaneous recurrence of methamphetamine psychosis.  Psychopharmacology, 1997, 13: 303-308.

12. Yui, K., Ishiguro, T., Goto, K., Ikemoto, S.: Factors affecting the development of spontaneous recurrence of methamphetamine psychosis. Acta Psychiatr. Scand, 1998, 97: 220-227.

13. Yui, K., Ishiguro, T., Goto, K., Ikemoto, S., Kamada, Y.: Spontaneous recurrence of methamphetamine psychosis: Increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change. Eur. Arch. Psychiatry Clin. Neurosci, 1999, 249: 103-111.

14. Yui, K., Goto, K., Ikemoto, S., Ishiguro, T., Kamada, Y.: Increased sensitivity to stress and episode recurrence in spontaneous recurrence of methamphetamine sychosis. Psychopharmacology, 1999, 145: 267-272.

15. Yui, K., Goto, K., Ikemoto, S., Ishiguro, T., Angrist, B., Duncan, G. E., Sheitman, B. B., Lieberman, J. A., Bracha, H. S., Ali, A. F.: Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: The role of  sensitization. Molecular Psychiatry, 1999, 4: 512-523.

16. Yui, K., Goto, K., Ikemoto, S., Ishiguro, T.: Stress induced spontaneous recurrence of methamphetamine psychosis: The relation between stresssful experiences and increased sensitivity to stress. Drug Alcohol. Depend, 2000, 58: 67-75.

17. Yui, K., Goto, K., Ikemoto, S., Ishiguro, T., Kamada, Y.: Increased sensitivity            to stress in spontaneous recurrence of methamphetamine psychosis: Noradrenergic hyperactivity with contribution from dopaminergic hyperativity. J. Clin. Psychopharmacol, 2000, 20: 165-174.

18. Yui, K., Goto, K., Ikemoto, S., Ishiguro, T.: Increased sensitivity to stresss associated with noradrenergic hyperactivity, involving dopaminergic hyperactivity in spontaneous recurrences of methamphetamine psychosis. Addict. Bio, 2000, 5: 343-350.

19. Yui, K., Ishiguro, T., Goto, K., Ikemoto, S.: Susceptibility to subsequent         episodes in spontaneous recurrences of methamphetamine psychosis. Ann. N. Y. Acad. Sci, 2000, 914: 292-302.

20. Yui, K., Ikemoto, S., Ishiguro, T., Goto, K.: Studies of amphetamine or methamphetamine psychosis in Japan: Relation of methamphetamine psychosis to schizophrenia. Ann. N. Y. Acad. Sci, 2000, 914: 1-12.

21. Nishijima, K., Yoshino, T., Yui, K., Kato, S.: Potent serotonin (5-HT) 2A receptor antagonists completely prevent the development of hypethermia and death in an animal model of 5-HT syndrome. Brain Res, 2001, 890: 23-31.

22. Yui, K., Goto, K,. Ikemoto, S., Nishijima, K., Yoshino, T., Ishiguro, T.: Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis. Drug Alcohol Depend, 2001, 64: 133-142.         

23. Yoshino, T., Nishijima, K., Yui, K., Kato, S.: Tandospirone potentiates the fluoxetine-induced increases in vivo dopamine release via 5-HT 1A receptors in rat medial frontal cortex. Neurochem. Int, 2002, 40: 355-360.

24.  Yui, K., Ikemoto, S., Goto, K., Nishijima, K., Yoshino, T., Ishiguro, T.: Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states: Susceptibility to psychotic states and implications for relapse of schizophrenia. Pharmacopsychiatry, 2002, 35:62-71.

25. Yui, K., Ikemoto, S., Goto, K: Susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis. Ann N.Y. Acad Sci, 2002, 914: 292-302.

26. Yui, K., Ikemoto, S., Goto, K, Nishijima, K., Kato, K: Susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis. J. Clin Psychopharmacol, 2003, 23: 525-528.

27. Yoshino, T., Nishijima, K., Yui, K., Kato, S.: Effects of haloperidol on serotonin syndrom. Neurosci Let, 2004, 364: 16-21.

28. Yui, K., Ikemoto, S., Goto, k.: The Role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence. Ann N.Y. Acad. Sci, 2004, 1025: 296-306.       

29. Yui, K., Suzuki, M., Kurachi, M.: Stress sensitization in schizophrenia. Ann N Y Acad Sci, 2007, 1113: 276-290.

30. Shioda, K., Nisijima, K., Yoshino, T,, Kuboshima, K., Iwamura, T., Yui, K., Kato, S: Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicol, 2008, 29(6):1030-6. Epub, Aug 5, 2008.

31. Yoshino, T., Nisijima, K., Shioda, K., Yui, K., Kato, S.: Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex. Neurosci Let, 2008, 438(1): 67-69.

32. Senoo, A., Okuya, T., Sugiura, Y., Mimura, K., Honda, Y., Tanaka, I., Kodama, T., Tokuno, H., Yui, K., Nakamura, S., Usui, S., Koshiba, M.: Effects of constant daylight exposure during early development on marmoset psychosocial behavior. Prog Neuropdsychophsr,macol Biol Psychiatry, 2011, 35(6):1493-8.

33. Yui, K., Koshiba, M., Nakamura, S., Ohnisi, M.: Efficacy of adding large doses of arachidonic acid to docosahexaenoic acid against restricted repetitive behavior in individuals with autism spectrum disorders: a placebo-controlled trial. Journal of Addiction Research & Therapy, 2011, dx.doi.org/10.4172/2155-6105.S4-006, 2011.

34. Yui, K., Koshiba, M., Nakamura, S., Kobayashi, Y.: Effects of large doses of arachidonic acid added to docosahexaenoic acid on social Impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled randomized trial. Journal of Clinical Psychopharmacology, 2012, 32(2): 200-206.

35. Yui, K., Nakamura, Shun., Koshiba, M.: Neurobiological bases and pharmacologic treatment of social impairment in autism spectrum disorders. Current Psychopharmacology, 2012, 1: 233-246.

36. Yui, K., Koshiba, M., Nakamura, Shun.: Effects of adding large doses of arachidonic acid to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders. Current Psychopharmacology, 2012, 2: 84-90.

37. Yui, K.: The role of arachidonic acid in the neuronal development related to psychiatric disorders. Current Psychopharmacology, 2012, 2: 54-57.

38. Koshiba, M., Senoo, A., Mimura, K., Shirakawa, Y., Karino, G., Obara, S., Ozawa, S., Sekihara, H., Fukushima, Y., Ueda, T., Kishino, H., Tanaka, T., Ishibashi, H., Yamanouchi, H., Yui, K., Nakamura, S.: A cross-species socio-emotional behaviour development revealed by a multivariate analysis. Sci Rep. 2013; 3:2630. doi: 10.1038/srep02630.

39. Yui, K.: Current pharmacologic treatments in impaired social interaction in autism spectrum disorders. Atta-ur-Rahman, FRS ed: Frontiers in Clinical Drug Research, Volume 1. Bentham Books, pp. 253-270. 2013.

40. Yui, K.: Pharmacological treatments, related clinical characteristics and brain function in adolescent depression in impaired social interaction in autism spectrum disorders. Atta-ur-Rahman, FRS ed: Frontiers in Clinical Drug Research, Volume 1. Bentham Books. pp. 270-282. 2013.

41 Yui, K., Ohnishi, M.: Plasma cortisol response to asked question on recent events during videogame playing in individuals with autism spectrum disorders. American Journal of Clinical Research Medicine, 2013, 1 (4): 65-70.

42. Yui K, Imataka G, Kawasaki Y. Competitive Interaction Between Plasma Omega-3 Fatty Acids and Arachidonic Acid is Related to Down-Regulation of A Signaling Mediator.Med Chem. 2016 Jan 6.

43. Yui K, Imataka G, Kawasaki Y, Yamada H. Down-regulation of a signaling mediator in association with lowered plasma arachidonic acid levels in individuals with autism spectrum disorders. Neurosci Lett. 2016 610:223-8.

44. Yui K, Imataka G, Kawasak Y, Yamada H. Increased ω-3 polyunsaturated fatty acid/arachidonic acid ratios and upregulation of signaling mediator in individuals with autism spectrum disorders.Life Sci. 2016 Jan 15;145:205-12. doi: 10.1016/j.lfs.2015.12.039. Epub 2015.

45. Yui K, Berk M. Mitochondrial Dysfunction and Its Relation to Translocator Protein, Oxidative Stress, mTOR Signaling, and Synaptic Protein.Mini Rev Med Chem. 2015;15(5):353-4.

46. Yui K. Editorial. New Targets of Medical Treatment in Psychiatric Disorders. Curr Neuropharmacol. 2015;13(6):736-8.

47. Yui K, Imataka G, Nakamura H, Ohara N, Naito Y. Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders. Curr Neuropharmacol. 2015;13(6):776-85.

48. Yui K, Sato A, Imataka G. Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders. Mini Rev Med Chem. 2015;15(5):373-89. Review.

49. Yui K, Imataka G, Kawasaki Y, Yamada H. Increased ω-3 polyunsaturated fatty acid/arachidonic acid ratios and upregulation of signaling mediator in individuals with autism spectrum disorders. Life sciences, 2016, 145: 205-12.

50. Yui K, Imataka G, Kawasaki Y. Competitive Interaction Between Plasma Omega-3 Fatty Acids and Arachidonic Acid is Related to Down-Regulation of A Signaling Mediator. Med Chem. 2016;12(4):318-27

51. Yui K, Kawasaki Y, Yamada H, Ogawa S. Oxidative Stress and Nitric Oxide in Autism Spectrum Disorder and Other Neuropsychiatric Disorders.CNS Neurol Disord Drug Targets. 2016;15(5):587-96.

52. Yui K. Editorial: New Therapeutic Targets for Autism Spectrum Disorders. CNS Neurol Disord Drug Targets. 2016;15(5):529-32

53. Yui K, Tanuma N, Yamada H, Kawasaki Y. Reduced endogenous urinary total antioxidant power and its relation of plasma antioxidant activity of superoxide dismutase in individuals with autism spectrum disorder. Int J Dev Neurosci. 2016 . pii: S0736-5748(16)30124-1. doi: 10.1016/j.ijdevneu.2016.08.00334.

54. Yui K, Tanuma N, Yamada H, Kawasaki Y. Decreased total antioxidant capacity has a larger effect size than increased oxidant levels in urine in individuals with autism spectrum disorder. Environ Sci Tollution Res (2017.1 reviserversion, ynder review).

55. Yui K, Tanuma N, Yamada H, Kawasaki Y. Decreased total antioxidant capacity has a larger effect size than increased oxi41 Yui, K., Imataka, G., Kawasaki, Y.: Competitive Interaction Between Plasma Omega-3 Fatty Acids and Arachidonic Acid is Related to Down-Regulation of A Signaling Mediator. Med Chem. 2016;12(4):318-27 

56 Yui,K., Tanuma, N., Yamada, H., Kawasaki, Y.: Reduced endogenous urinary total antioxidant power and its relation of plasma antioxidant activity of superoxide dismutase in individuals with autism spectrum disorder. Int J Dev Neurosci. 2016 Aug 21. pii: S0736-5748(16)30124-1. doi: 10.1016/j.ijdevneu.2016.08.00334.

57. Yui, K., Naoyuki Tanuma, Hiroshi Yamada, Kawasaki, Y. Decreased total antioxidant capacity has a larger effect size than increased oxidant levels in urine in individuals with autism spectrum disorder. Environ Sci Tollution Res (. 2017 Apr;24(10):9635-9644.

58 Yui K. et al. Improvement in Impaired Social Cognition but Not Seizures by Everolimus in a Child with Tuberous Sclerosis-Associated Autism through Increased Serum Antioxidant Proteins and Oxidant/Antioxidant Status. Case Rep Pediatr. 2019;2019:2070619.

59 Yui K. et al. Improvement in Impaired Social Cognition but Not Seizures by Everolimus in a Child with Tuberous Sclerosis-Associated Autism through Increased Serum Antioxidant Proteins and Oxidant/Antioxidant Status. Case Rep Pediatr. 2019;2019:2070619.

60 Yui K. et al. Lipid Peroxidation With Implication of Organic Pollution in Autistic Behaviors. Cureus. 2021 Mar 30;13(3):e14188.

61 Yui K. et al. The role of lipid peroxidation in individuals with autism spectrum disorders. Metab Brain Dis. 2020;35(7):1101-1108. .Metab Brain Dis. 2020. PMID: 32643093

62 Yui K. et al. Contribution of Transferrin and Ceruloplasmin Neurotransmission and Oxidant/Antioxidant Status to the Effects of Everolimus: A Case Series. Cureus. 2020;12(2):e6920.

63. Urinary and Plasma Antioxidants in Behavioral Symptoms of Individuals with Autism Spectrum Disorder

 Imataka G a, Kunio Yui K*, Yuki S, Kawasaki Y, Sasaki H, Shiroki R, Yosihara A. Frontiers inPsychiatry (In press, 2021, 6)

 

 「和文論文」

 

 

オメガ-6 脂肪酸アラキドン酸のシグナリング調整と自閉症スペクトラム障害状の改善.。油井 邦雄 , 川崎 洋平 , 山田 浩. 日本本生物学的精神医学会誌 27(1), 41-47, 2016

 

自閉症スペクトラム障害の病態類型とバイオマーカー,治療方向性

油井 邦雄 

日本生物学的精神医学会誌 26(3), 146-153, 2015

 

脳ペプタイドに関わる精神神経疾患の病態と治療的展望:ミトコンドリアの機能障害との関連

油井 邦雄

日本生物学的精神医学会誌 25(2), 85-89, 2014

 

自閉症スペクトラム障害の社会的相互性障害に対する治療薬の効果の比較・検討

油井 邦雄

精神神經學雜誌114(8), 934-940, 2012-08-25

 

アラキドン酸の社会性障害に対する効果と血漿濃度

油井 邦雄 , 小柴 満美子 , 中村 俊 , 大西 雅子

日本神経精神薬理学雑誌 31(3), 117-124, 2011-06-25

 

社会性障害とアラキドン酸の作用機序

油井 邦雄 , 小柴 満美子 , 中村 俊

日本生物学的精神医学会誌 22(1), 29-34, 2011-03-25

 

自閉症スペクトラム障害の社会性障害におけるアラキドン酸の役割について

油井 邦雄 , Murphy Declan , 濱川 浩

精神神經學雜誌111(11), 1387-1396, 2009-11-25

 

アスペルガー障害の生物学的病態と治療 : アラキドン酸の臨床効果

油井 邦雄 , MURPHY Declan , 濱川 浩

脳と精神の医学 20(2), 133-142, 2009-06-25

 

アスペルガー障害の脳機能病態と治療

油井 邦雄 , Murphy Declan

精神神經學雜誌 110(10), 912-920, 2008-10-25

 

統合失調症のストレス脆弱性の形成様態

油井 邦雄 , 西嶋 康一 , 渡邉 孝一

精神神經學雜誌  777-785, 2007-08-25

 

メタンフェタミン(methamphetamine)およびストレスによる過敏反応(sensitization)

油井 邦雄 , 池本 卯典

日本神経精神薬理学雑誌 24(3), 151-157, 2004-06-25

 

女性精神医学の方向性

油井 邦雄

精神神經學雜誌106、213-219, 2004-02-25

 

覚せい剤精神病の自然再燃(フラッシュバック現象)の発現過程と対策

油井 邦雄 , 池本 卯典 , 後藤 公彦

日本神経精神薬理学雑誌21(5), 183-185, 2001-11-25

 

ワークショップ : Evolution and Update of Detoxification Techniques for Opiate Addicts

油井 邦雄

日本神経精神薬理学雑誌 20(4), 175-177, 2000-10-25

 

非定型抗精神病薬 olanzapine の臨床効果

油井 邦雄

日本神経精神薬理学雑誌 19(3), 101-110, 1999-06-25

 

シンポジウム : Neurobiological Basis of Stimulant-Induced Sensitization : From Animals to Man

油井 邦雄

日本神経精神薬理学雑誌18(4), 149-152, 1998-08-25

 

シンポジウム : Neurobiological Basis of Relapse Prediction in Stimulant-Induced Psychosis and Schizophrenia

油井 邦雄

日本神経精神薬理学雑誌 16(5), 201-203, 1996-10-25

 

覚醒剤精神病のフラッシュバック現象を呈した症例

油井邦雄

脳と精神の医学 2, 627-631, 1991

 

メトアンフェタミン, スコポラミン同時投与による常同行動と行動上の過敏反応(逆耐性現象)

油井 邦雄

弘前医学 39(3), 447-466, 1987-07

 

青春期周期性精神病の脳波 (精神疾患<今月のテ-マ>)

石黒 健夫 , 油井 邦雄

臨床脳波 23(2), p90-99, 1981-02

 

思春期女性の周期性精神病における脳波像の変化と間脳機能 (思春期精神障害と脳波<今月のテ-マ>)

油井 邦雄 , 石黒 健夫

臨床脳波 22(6), p391-403, 1980-06

 

入眠期における前頭部δ波 (ナルコレプシ-<今月のテ-マ>)

石黒 健夫 , 諏訪 克行 , 油井 邦雄

臨床脳波 20(2), p86-94, 1978-02

 

思春期の周期性精神病に対する治療法の開発

油井邦雄

精神薬療基金研究年報 9, 202-211, 1977

 

視床下部通電刺激による雄ネズミ乳腺における乳汁産生の誘起

油井 邦雄, 益田 栄

順天堂医学 17(1), 80-84, 1971

 

英文著書 

1  Yui, K.: Biological Psychiatry Today, 2A: The neuroendocrinological investigation of periodic psychosis at adolescence. In  Obiols, J., Ballus, C., Gonzales Monclus, E. and Pujor, I. (Eds.). 1979、P. 746ー752, Elsevier/North-Holland Biomedical Press, Amsterdam, New York, Oxford.

2 Yui K, Goto K, Ikemoto S, Ishiguro T.Monoamine neurotransmitter function ans sponteneous recurrence of methamphetamine psychosis. in「Neuobiological Mechanisms of Drugs Abuse, VAnnals of the New York Academy of Scienceolume 801,; 2000】p415-429

3 Yui K, Ikemoto S, Ishiguro T:Studies of amphetamine or methamphetamine psychosis in japan. in「Neuobiological Mechanisms of Drugs Abuse, Volume  924,; 2000】p1-123 Yui K, Ikemoto S, Goto K. Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis. in「Neuobiological Mechanisms of Drugs Abuse, Annals of the New York Academy of ScienceVolume 965, 2002】p292-304

4  Yui K, Ishiguro T, Goto K, Ikemoto S: Susceptability to subsequent episodes in spontaneous recurrence of methamphetamine psychosis. in「Neuobiological Mechanisms of Drugs Abuse,Annals of the New York Academy of Science, Volume 914;  2000】p292-302.

5 Yui K, Goto K, Ikemoto S, Therole of noradrenalinergic and dopaminergic hyperactivity in the development of spontaniusrecurrence of methamphetamine psychosis and susceptibility to episode recuttence.in 「Neuobiological Mechanisms of Drugs Abuse, Annals of the New York Academy of Science, Volume 1025; 2004】p296-306.

6 Yui K, Suzuki M, Kurachi M.Stress sensetization in schiziphrenia. in [Stress responses in biology and medecine], Annals of the New York Academy of Science, volume 1113. p276-290

 

和文著書

1   宮本忠雄,油井邦雄:欝(うつ)病―管理社会のゆううつーうつ病研究小史.融道男,山本和郎,大原健士郎編、1977,P. 235―244,有斐閣,    東京都.

2    油井邦雄:青春期周期性精神病の病態と心身との 関連.佐藤時治郎教授還暦記念業績集.1983,P. 550―554,弘前大学医学部神経精神医学教室,弘前市.

3    油井邦雄,三浦隆男,久保善明:メトアンフェタミン,スコポラミン同時投与における常同行動と行動上の過反応性(逆耐性現象)について.難波益之(編): 生物学的精神医学最近の進歩,1985,P. 126―133,ヘスコインタ―ナショナル,東京都.

4    三浦隆男,油井邦雄:メトアンフェタミン,アトロピン同時投与における常同行動と行動上の過敏反応性(逆耐性現象- 隔離飼育と集団飼育における比較-.(難波益之編):生物学的精神医学最近の進歩,1985,P.134―141,ヘスコインターナショナル,東京都.

5    油井邦雄:「Joseph, M. H.:分裂病におけるドーパミンと認知機能」につい て.福島 裕編:佐藤時治郎教授退官記念業績集,1987,P.103−110,弘前大学医学部精神経医学教室,弘前市.

6    油井邦雄:総論:女性性の概念と実証的検討. 宮本忠雄(監修),油井邦雄(編):女性性の病理と変容―現代社会における女性性とその逸脱構造.1995,P.1―26,新興医学版社,東京都.

7  油井邦雄:女性性に関する生物学特性. 宮本忠雄(監修),油井邦雄(編): 女性性の病理と変容―現代社会における女性性とその逸脱構造.1995,P.   174―182,新興医学版社,東京都.

8    油井邦雄,後藤公彦,池本卯典:覚醒剤精神病のフラッシュバック現象を惹起 した 症    例―その定義と発現過程の検討 .宮本忠雄(監修):現代精神医学の 20年:宮本 忠雄教授退官記念論文集,1995,P.359―365,星和書店,東京都.

9. 油井邦雄、後藤公彦、池本卯典。覚せい剤精神病のフラッシュバック現象を惹起した症例、現代精神医学の20年、清和書店、p.359ー365, 1995年

10    油井邦雄:メトアンフェタミン,スコポラミン同時投与における常同行動と行動上の過敏反応性(逆耐性現象).I弘前大学医学部神経精神医学教室(編):    福島 裕退官記念学位論文集:p10-29, 1995年

10    油井邦雄:「女性のメンタルヘルスケアーの現状と展望」. 油井邦雄、相良洋子、加茂登志子編集「実践 女性精神医学」、P. 1-24、創造出版社、東京都、2005年5月

 

3.総説

英文総説

1   Yui, K. and Ishiguro, T.: The psychosomatic investigation and treatment of periodic psychosis of puberty.  The 4th Congress of the International College of  Psychosomatic Medicine, Proceedings, p. 619-623; 1977.

2   Yui, K. and Ishiguro, T.: The psychosomatic investigation and treatment of periodic psychosis of puberty. The 4th Congress of the International College of Psychosomatic Medicine, Proceedings, p.  619-623; 1977.

                           

4. 学会発表

  国際会議:シンポジウム

1  Yui, K. and Ishiguro, T.:「Hormone in Psychiatry」, Neuroendocrinological  correlation of periodic psychosis at adolescence. IInd World Congress of Biological Psychiatry, Barcelona, 1978.

2  Yui, K.: 「Vulnerability to schizophrenic symptoms」, Flashbacks in methamphetamine psychosis: psychological aspects. The Satellite Symposium of the XVIIth Collegium Internationale Neuro-Psychooharmacologicum (CINP), Sendai, 1990.

3  Goto, K., Yui, K. and Ikemoto, S.: 「Instrumental Analysis 2」, Analysis of amine in blood plasma of the people of methamphetamine abuse. International Symposium of Forensic Science Tokyo: International Workshop on Impurity Profiling Analysis of Illicit Drugs, Tokyo, 1993.

4   Yui, K.: Plenary  session 「Biological aspects of substance abuse」: Therapeutic treatment for  flashbacks in methamphetamine psychosis. World Congress Japan on Penitentiary (Prison)  Health Care and Treatment of Offenders (ICPMS), Tokyo, 1994.

5   Yui, K., Goto,  K. and Ikemoto, S. :「Clinical evidence for stimulant-induced sensitization」: Flashbacks in methamphetamine psychosis. XIXth CINP  Congress, Washington, D.C., 1994.

6   Yui, K., Goto, K., Ikemoto, S. and  Ishiguro, T.: Flashbacks inmethamphetamine psychosis and monoamine neurotransmitter function. Satellite Meeting of 15th International  Society for Neurochemistry,「Cellular and Molecular Mechanisms of Drugs of Abuse: Cocaine, Ibogaine  and Substituted Amphetamines], Niigata,1995.

7   Yui, K., Goto, K.,  Ikemoto, S. and Ishiguro, T.: Monoamine neurotransmitter function and  spontaneous recurrence of methamphetamine psychosis. Official Satellite Symposium of 15th International Society for Neurochemistry「Neuromediators and brain dysfunction」, Tokyo, 1995.

8    Yui, K., Goto, K.,  Ikemoto, S. and Ishiguro, T.:「Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia」:  Noradrenergic  hyperactivity and spontaneous recurrence of methamphetamine psychosis. XXth CINP Congress, Melbourne, 1996.

9    Yui, K., Goto, K.,  Ikemoto, S. and  Ishiguro, T.:「Neurotoxicity of drugs of abuse」: Sensitization effects and methamphetamine psychosis. 2nd International Conference on Drug Abuse, Hongkong, 1997

10    Yui, K., Ishiguro,  T., Goto, K. and Ikemoto, S. : 「Neurobiological  basis of         stimulant- induced sensitization: From  animals to man」: The role of stress   sensitization  associated with  the poredominance of noradrenergic over   hyperactivity in spontaneous recurrences  of  methamphetamine psychosis.   XXIst CINP Congress, Glasgow, 1998.

11   Yui, K., Ishiguro,  T., Goto, K. and Ikemoto, S. : Increased sensitivity to stresss and episode recurrence in spontaneous recurrence of methasmphetamine psytchosis. Satellite Meeting of the International Society for Neurochemistry and European Society for Neurochemistry,「Cellular and Molecular Mechanisms of Drugs of Abuse: Cocaine, Ibogaine and Substituted  Amphetamines],  Copenhagen, 1999.

12   Yui, K.: Educational workshop: 「Evaluation and update detoxification techniques for opiate addicts」: Neurophsiological basis of opiate detoxification.  XXIInd CINP Congress, Brussels, 2000.

13   Yui, K.: Spontaneous recurrence of methamphetamine psychosis: Monoamine neurotransmitter function and susceptibility to episode recurrence.  International Conference on the Stimulant- Induced Psychosis. Sendai, 2001.

14   Yui, K., Bracha Hs, Nishijima, K. Symposium: 「Vulnerabilityto the  developmenbt of schizophrenia」, Early stress in the development of  schizophrenia.  XIIth World Congress of Psychiatry (WPA), Yokohama, 2002.

15     Yui, K, Ikemoto, S., Goto, K. Workshop: 「Sensitization in methamphetamine   psychosis and schizophrenia」, Stress sensitization in pontaneous recurrence  of methamphetamine psychosis. XIIth WPA, Yokohama, 2002.

16   Yui, K, Ikemoto, S: The role of noradrenergic and dopaminergic hyperactivity in  the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence. International Society for  Neurochemistry and Japanese Forum on Nicotin and Drug Dependence. Studies, Satellite Meeting, Kyoto, 2003.

17  Yui, K., Nihijima K.:  Symposium:「Neurobiological vulnerability to schizophrenia」, Stress lines in molars as an objective marker of early stress and vulnerability to adult psychopathology. The 7h World Congress of Biological Psychiatry, Sidney, February, 2004.

18    Yui, K, Ikemoto, S: Braking Scientific News session: Stress sensitization iin episode recurrence of spontaneous recurrence of methamphetamine psychosis in favor of noradrenergic hyperactivity, and its relation to the development of  the symptoms of schizophrenia in favor of dopaminergic hyperactivity. XXIV CINP Congress. Paris, June, 2004.

19    Yui, K., Nishijima, K., Watanabe, K, Kobayashi, M., Ishibashi, K., Inoue H.  Symposium : [Neurobiological susceptibility to schizophrenia], Exposure to emotional stress during early puberty and susceptibility to schizophrenia.

The 8 World Congress of Biological Psychiatry, Vienna, June 29- July 2, 2005

20  Yui, K., Nishijima, K., Watanabe, K, Kobayashi, M., Ishibashi, K., Inoue H. Exposure to emotional stree during early puberty and susceptability to schizophrenia. Symposium : [Neurobiological susceptibility to schizophrenia]. 2nd World Conference of stress, Budapest, 2008.

21  Yui, K., Nishijima, K., Yoshino, T. Causal role of stress sensitization in the development of spontaneous recurrence of methamphetamine psychosis. Symposium: [Stress sensitization in spontaneous recurrence of methamphetamine psychosis, schizophrenia and depression]. XXVI CINP Congress. Munich, July, 2008.

22  Yui, K., Neruropsysiological biomarker of impaired social interaction. XXviii. CINP Congress. Stockholm, June, 2012.

 

MISC

国内会議:シンポジウム

1   油井邦雄,石黒健夫:「脳波の発生機序をめぐって」:青春期の周期性精神病       における間脳機能と脳波.第7回脳波筋電図学会学術大会,1977.

2   油井邦雄:「覚せい剤依存者の特質とその処遇」,覚醒剤精神病者の臨床特性.      第37回日本矯正医学会,1990.

3   油井邦雄:「現代社会における女性性と逸脱様態」:女性性の変遷と日本にお       ける現勢.第11回日本心理臨床学会,1992.

  4    油井邦雄:「ここまで進んだ覚せい剤精神病の発現機序ーよりよき治療を目        指して」: 覚醒剤精神病の自然再燃の発現過程と治療指針.第4回ニコチン,   薬物依存研究ホーラム,2001.

  5  油井邦雄:「月経関連医学研究会」、記念講演:月経関連ホルモンと精神症状:病態と治療. 2003. 

6   油井邦雄:シンポジウム「女性精神医学の提案」、女性精神医学の方向性.. 第99回日本精神神経学会.2003.

7    油井邦雄:ワークショップ「女性のメンタルヘルスケアーの課題とその診療指針」:問題提起、診療主体は女医か男女混合か、診療支援か単独科か、語りかジェンダーか. 第101回日本精神神経学会、2005.

8    油井邦雄、西嶋康一:ワークショップ「methylpenidate(リタリン)はうつ病治療に必要か」:リタリンの有効な用法. 第101回日本精神神経学会、2005.大宮市.

 9    油井邦雄:自閉症スペクトラム障害とADHDの新規治療薬お奏功機序. 19回日本臨床精神神経薬理学会、第39回日本神経精神薬理学会合同年会、2009、京都市.

10    油井邦雄: 自閉症スペクトラム障害における不飽和脂肪酸の役割と治療効果. 第20回日本臨床精神神経薬理学会、第40回日本神経精神薬理学会合同年会、2009、仙台市.

11    油井邦雄: 自閉症スペクトラム障害の抗酸化能と治療的展開. 第24回日本臨床精神神経薬理学会、第44回日本神経精神薬理学会合同年会、2014、名古屋市.

 

「日本精神神経学会シンポジウム」

1   油井邦雄、西嶋康一、渡辺幸一、小林正義他:統合失調症のストレス脆弱性の形成様態:フラッシュバック現象との関連、第103回日本精神神経学会シンポジウム「統合失調症におけるストレス脆弱性の様態」2007年、高知市

 2     油井邦雄、デクレンン マルファイ アスペルガー障害の脳機能病態と治療:脂肪酸動態と治療効果。シンポジウム「発達障害の病態と治療」.第104回日本精神神経学会シンポジウム「統合失調症におけるストレス脆弱性の様態」2007年、福岡市

3     油井邦雄:社会性障害におけるアラキドン酸の役割について。シンポジウム「発達障害の病態と治療」.第105回日本精神神経学会シンポジウム「自閉症スペクトラム障害の社会性障害の病態と治療的展開」2009年、神戸市

4    油井邦雄、Declan Murphy: 自閉症スペクトラム障害の社会性障害に対するアラキドン酸の改善効果と神経発達促進効果:Double-blind placebo-controlled trialでの検索。第106回日本精神神経学会シンポジウム「発達障害の思春期、青年期の診断と医学的ケアー」、2010年、広島市

5   油井邦雄: 自閉症スペクトラム障害の社会性障害の治療薬の比較。第108回日本精神神経学会シンポジウム「社会性に関わる脳機能の異常と環境因子との関連」、2012年、札幌市

6    油井邦雄: 自閉症スペクトラム障害例におけるテレビゲームのストレス緩和作用. 第109回日本精神神経学会シンポジウム「社会性に関わる脳機能の異常と環境因子との関連」、2013、福岡市

7    油井邦雄: アラキドン酸を主としたomega-6/DHAを主としたomega-3の含有比が4;1の製品による社会性障害の著明改善. 第110回日本精神神経学会シンポジウム「自閉症スペクトラム障害の実践的治療の展開」、2014、横浜市

8    油井邦雄: 自閉症スペクトラム障害における情報伝達タンパクの機能不全の修復 による治療効果. 第112回日本精神神経学会シンポジウム「精神疾患の病態検索とそれにもとづく治療の効果」、2016、東京都

 

 


Papers

  24

Research Projects

  14